Developer docs
API playgroundTry for free, no card

Search company profiles

Avanzanite Bioscience

Full company profile

uuid0005g6q

Namestring
Avanzanite Bioscience
Legal namestring
Avanzanite Bioscience B.V.
Websiteurl
avanzanite.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Avanzanite Bioscience B.V. is a privately-held, Amsterdam-based specialty pharmaceutical company founded in 2022 that operates a pan-European commercialization platform for orphan medicines across 32 countries in the European Economic Area, the United Kingdom, and Switzerland. The company holds a Wholesale Distributor Authorization (WDA) license (no. 109223 G) issued by the Dutch Competent Authorities, enabling it to act as a fully authorized distributor of medicinal products within Europe. Avanzanite partners with emerging and mid-sized biopharmaceutical originators through exclusive licensing and distribution agreements, offering end-to-end commercialization capabilities including regulatory navigation, market access, pricing and reimbursement, medical affairs, and distribution—services that the target biotech firms would otherwise have to build independently at significant cost.

The company's commercialized portfolio comprises three products secured through three strategic alliances established in three years: PYRUKYND® (mitapivat) under an exclusive 2025 agreement with Agios Pharmaceuticals for the European Economic Area, UK, and Switzerland; SIBNAYAL® under an exclusive 2023 distribution agreement with Advicenne across Germany, Austria, Switzerland, Liechtenstein, Greece, Ireland, Cyprus, and Malta; and AKANTIOR® under an exclusive 2022 license and supply agreement with SIFI S.p.A. across 26 EEA countries and Switzerland. As of May 2026, Avanzanite has led four rare disease product launches in Europe, including the May 2026 European Commission approval of PYRUKYND for thalassemia. Revenue is generated through product sales, milestone payments, and royalties under these licensing/distribution arrangements.

Avanzanite's go-to-market is an enterprise field sales model targeting biotech originators, supported by a 'Champions League' team of more than 90 rare disease pharma professionals as of March 2026, growing to over 100 by May 2026. The company has established dedicated country leadership in priority markets including France (General Manager Constance Sabbagh, March 2026) and Spain (Country Manager María Baquerizo López-Quectuy, June 2026). In November 2025, Avanzanite closed its first institutional funding round—a €32 million Series A led by MVM Partners—to scale infrastructure across all 32 European countries, support ongoing product launches, and pursue further alliances and acquisitions.

Short descriptiontext

Avanzanite Bioscience is a pan-European specialty pharmaceutical company that commercializes and distributes orphan medicines across 32 European countries on behalf of biotech originators through exclusive licensing and distribution agreements. Founded in 2022 and headquartered in Amsterdam, it offers end-to-end market access, pricing, regulatory, medical affairs, and distribution services for rare disease therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orphan drug commercialization, rare disease medicines, specialty pharmaceutical distribution, pan-European market access, licensing partnerships
Industry3 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals / Orphan Drug Commercialization
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Distribution Partnerships
TypeLicensing Royalties
Description

Avanzanite earns revenue through exclusive licensing and distribution agreements with biotech/pharma originators for commercialization of orphan medicines across Europe. Revenue is generated via product sales, milestone payments, and potentially royalties from commercialized rare disease therapies.

avanzanite.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1PYRUKYND
Description

Oral pyruvate kinase activator for treatment of PK deficiency and thalassaemia, commercialized by Avanzanite across Europe under partnership with Agios Pharmaceuticals.

avanzanite.com
+2 more records
Core offering1 text field

Avanzanite offers end-to-end commercialization and distribution partnerships to research-based biopharmaceutical originators, licensing their approved or late-stage orphan medicines and bringing them to patients across 32 European countries. The company handles regulatory navigation, pricing and reimbursement, market access, medical affairs, and physical distribution, enabling biotech innovators to unlock European value of their rare disease therapies without building local infrastructure. Three products are currently commercialized under this model: PYRUKYND, Sibnayal, and AKANTIOR.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Revenue tripled year-over-year in Q3 2025 and climbed over 20% quarter-on-quarter
+2 more records
Product overview1 text field

Avanzanite Bioscience operates as a pan-European specialty pharmaceutical company offering end-to-end commercialization and distribution partnerships for rare disease medicines. The company provides a unified platform spanning 32 European countries through three commercialized products: PYRUKYND® (mitapivat) for pyruvate kinase deficiency and thalassaemia, Sibnayal® for distal Renal Tubular Acidosis, and AKANTIOR® for Acanthamoeba Keratitis. These products are secured through exclusive licensing and distribution agreements with partner pharmaceutical companies (Agios Pharmaceuticals, Advicenne, and SIFI respectively), enabling biotech innovators to unlock the full European commercial potential of their orphan medicines without building local infrastructure.

Product and service4 records
1PYRUKYND (mitapivat)
CategoryOrphan Pharmaceutical Product
Description

An oral pyruvate kinase (PK) activator approved by the European Commission in 2022 for adults with Pyruvate Kinase (PK) Deficiency and in 2026 for anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia. Commercialized by Avanzanite under exclusive agreement with Agios Pharmaceuticals across the EEA, UK, and Switzerland for healthcare providers treating these rare hematological conditions.

2Sibnayal
CategoryOrphan Pharmaceutical Product
Description

A medicinal product approved by the European Commission in 2021 for the treatment of distal Renal Tubular Acidosis (dRTA), a rare kidney disease. Distributed by Avanzanite under an exclusive distribution agreement with Advicenne across Germany, Austria, Switzerland, Liechtenstein, Greece, Ireland, Cyprus, and Malta for patients with this rare renal condition.

3AKANTIOR
CategoryOrphan Pharmaceutical Product
Description

A medicinal product approved by the European Commission in 2024 for the treatment of Acanthamoeba Keratitis, a rare and severe ophthalmologic parasitic infection that accounts for 50% of blindness among contact lens users. Commercialized by Avanzanite under exclusive license and supply agreement with SIFI across 26 countries within the European Economic Area and Switzerland for affected patients and their treating ophthalmologists.

4Pan-European Orphan Drug Commercialization Partnership
CategoryCommercialization & Distribution Service
Description

End-to-end commercialization and distribution partnership service for emerging or early-stage biopharmaceutical originators with approved or late-stage orphan medicines. The service covers regulatory navigation, pricing and reimbursement negotiations, market access, medical affairs, and WDA-licensed physical distribution across 32 European countries (EEA, UK, Switzerland) under bespoke exclusive licensing or distribution agreements. Targeted at biotech originators that lack European infrastructure or face regulatory and market access complexity.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Avanzanite entered an exclusive agreement with Agios Pharmaceuticals in June 2025 to commercialize and distribute PYRUKYND (mitapivat) across the European Economic Area, UK, and Switzerland. PYRUKYND is a first-in-class oral pyruvate kinase activator approved for adults with PK deficiency and later for thalassemia. The partnership includes rights for potential future indications and represents Avanzanite's flagship rare disease launch.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-01
Description

Agios Pharmaceuticals established a revenue-sharing partnership with NewBridge Pharmaceuticals for the GCC region to commercialize PYRUKYND ex-U.S., pending regulatory approvals in those markets. Avanzanite is the equivalent partner for the European market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-01
Description

Avanzanite signed an exclusive distribution agreement with Paris-based Advicenne for Sibnayal (ADV 7103), a medicinal product approved by the European Commission for the treatment of distal Renal Tubular Acidosis (dRTA). Avanzanite distributes Sibnayal in Germany, Austria, Switzerland, Greece, Ireland, Cyprus, and Malta, with first anticipated commercial launch in Germany in mid-2023.

4SIFI S.p.A.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Avanzanite holds exclusive license and supply agreement with SIFI for AKANTIOR (Acanthamoeba Keratitis treatment) across 26 countries within the EEA and Switzerland. SIFI partnered with Avanzanite to commercialize and distribute its investigational ultra-orphan medicine for the treatment of AK, a devastating eye infection that accounts for 50% of blindness among contact lens users.

avanzanite.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Alexion, operating as AstraZeneca's Rare Disease unit, is a global leader in commercializing rare disease therapeutics with established European infrastructure. Highly comparable therapeutic and commercial focus but at vastly larger scale and within a broader pharma portfolio.

TypeBroad incumbent
Description

BioMarin is a global biotechnology company focused exclusively on rare diseases with significant European commercial presence. Comparable orphan drug focus but with proprietary pipeline rather than in-licensed assets.

TypeEmerging player
Description

Ultragenyx is a mid-stage rare disease biotech commercializing multiple orphan therapies in Europe and globally. Comparable focus on ultra-rare diseases and European commercialization, though Ultragenyx owns its pipeline.

TypeBroad incumbent
Description

Chiesi is a privately-held European-headquartered pharmaceutical company with a strong rare disease franchise (Chiesi Global Rare Diseases). Comparable focus on commercializing orphan drugs across European markets with established country-level infrastructure.

TypeDirect peer
Description

Sobi is a Swedish-headquartered global biopharmaceutical company specializing in rare diseases across haematology, immunology and specialty care with deep pan-European commercialization infrastructure. Highly comparable to Avanzanite's orphan drug commercialization focus and European footprint.

TypeEmerging player
Description

Orphalan is a European specialty pharmaceutical company focused exclusively on rare diseases, developing and commercializing orphan drugs across multiple European markets. Comparable focus on rare disease commercialization in Europe.

TypeDirect peer
Description

Recordati Rare Diseases is a global pharmaceutical group with a dedicated rare disease business that acquires, licenses and distributes orphan drugs across Europe and the US. Comparable business model of in-licensing and commercializing rare disease products across multiple geographies.

TypeDirect peer
Description

Inceptua is a specialty pharmaceutical company providing commercialization, distribution and early access services for rare disease and specialty products across Europe. Comparable business model of helping biotech originators access European markets without building own infrastructure.

TypeDirect peer
Description

Tanner Pharma provides specialty distribution, commercialization and managed access services for rare disease products globally. Comparable outsourced commercialization model targeting emerging biopharmaceutical companies.

TypeEmerging player
Description

Theramex is a global specialty pharmaceutical company focused on women's health and rare conditions across Europe with established country-level infrastructure. Comparable European rare disease commercialization focus within a narrower therapeutic scope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avanzanite Bioscience

Specialty Pharmaceuticals / Orphan Drug Commercializationavanzanite.com

Avanzanite Bioscience is a pan-European specialty pharmaceutical company that commercializes and distributes orphan medicines across 32 European countries on behalf of biotech originators through exclusive licensing and distribution agreements. Founded in 2022 and headquartered in Amsterdam, it offers end-to-end market access, pricing, regulatory, medical affairs, and distribution services for rare disease therapies.

What Avanzanite Bioscience does

Avanzanite Bioscience B.V. is a privately-held, Amsterdam-based specialty pharmaceutical company founded in 2022 that operates a pan-European commercialization platform for orphan medicines across 32 countries in the European Economic Area, the United Kingdom, and Switzerland. The company holds a Wholesale Distributor Authorization (WDA) license (no. 109223 G) issued by the Dutch Competent Authorities, enabling it to act as a fully authorized distributor of medicinal products within Europe. Avanzanite partners with emerging and mid-sized biopharmaceutical originators through exclusive licensing and distribution agreements, offering end-to-end commercialization capabilities including regulatory navigation, market access, pricing and reimbursement, medical affairs, and distribution—services that the target biotech firms would otherwise have to build independently at significant cost.

The company's commercialized portfolio comprises three products secured through three strategic alliances established in three years: PYRUKYND® (mitapivat) under an exclusive 2025 agreement with Agios Pharmaceuticals for the European Economic Area, UK, and Switzerland; SIBNAYAL® under an exclusive 2023 distribution agreement with Advicenne across Germany, Austria, Switzerland, Liechtenstein, Greece, Ireland, Cyprus, and Malta; and AKANTIOR® under an exclusive 2022 license and supply agreement with SIFI S.p.A. across 26 EEA countries and Switzerland. As of May 2026, Avanzanite has led four rare disease product launches in Europe, including the May 2026 European Commission approval of PYRUKYND for thalassemia. Revenue is generated through product sales, milestone payments, and royalties under these licensing/distribution arrangements.

Avanzanite's go-to-market is an enterprise field sales model targeting biotech originators, supported by a 'Champions League' team of more than 90 rare disease pharma professionals as of March 2026, growing to over 100 by May 2026. The company has established dedicated country leadership in priority markets including France (General Manager Constance Sabbagh, March 2026) and Spain (Country Manager María Baquerizo López-Quectuy, June 2026). In November 2025, Avanzanite closed its first institutional funding round—a €32 million Series A led by MVM Partners—to scale infrastructure across all 32 European countries, support ongoing product launches, and pursue further alliances and acquisitions.

Avanzanite Bioscience firmographics

Firmographics
Name
Avanzanite Bioscience
Legal name
Avanzanite Bioscience B.V.
Website
https://avanzanite.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Avanzanite Bioscience is a pan-European specialty pharmaceutical company that commercializes and distributes orphan medicines across 32 European countries on behalf of biotech originators through exclusive licensing and distribution agreements. Founded in 2022 and headquartered in Amsterdam, it offers end-to-end market access, pricing, regulatory, medical affairs, and distribution services for rare disease therapies.
Ownership category
akta.pro rank

Avanzanite Bioscience industry classification

Industry
Product category
Specialty Pharmaceuticals / Orphan Drug Commercialization
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Orphan drug commercialization
  • Rare disease medicines
  • Specialty pharmaceutical distribution
  • Pan-European market access
  • Licensing partnerships

Where Avanzanite Bioscience is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

Avanzanite Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others

Revenue model

  1. Licensing and Distribution Partnerships: Avanzanite earns revenue through exclusive licensing and distribution agreements with biotech/pharma originators for commercialization of orphan medicines across Europe. Revenue is generated via product sales, milestone payments, and potentially royalties from commercialized rare disease therapies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Avanzanite Bioscience product offering

Product offering

Core offering

Avanzanite offers end-to-end commercialization and distribution partnerships to research-based biopharmaceutical originators, licensing their approved or late-stage orphan medicines and bringing them to patients across 32 European countries. The company handles regulatory navigation, pricing and reimbursement, market access, medical affairs, and physical distribution, enabling biotech innovators to unlock European value of their rare disease therapies without building local infrastructure. Three products are currently commercialized under this model: PYRUKYND, Sibnayal, and AKANTIOR.

Product overview

Avanzanite Bioscience operates as a pan-European specialty pharmaceutical company offering end-to-end commercialization and distribution partnerships for rare disease medicines. The company provides a unified platform spanning 32 European countries through three commercialized products: PYRUKYND® (mitapivat) for pyruvate kinase deficiency and thalassaemia, Sibnayal® for distal Renal Tubular Acidosis, and AKANTIOR® for Acanthamoeba Keratitis. These products are secured through exclusive licensing and distribution agreements with partner pharmaceutical companies (Agios Pharmaceuticals, Advicenne, and SIFI respectively), enabling biotech innovators to unlock the full European commercial potential of their orphan medicines without building local infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

  • PYRUKYND: Oral pyruvate kinase activator for treatment of PK deficiency and thalassaemia, commercialized by Avanzanite across Europe under partnership with Agios Pharmaceuticals.
  • SIBNAYAL
  • AKANTIOR

Products and services

  • PYRUKYND (mitapivat) An oral pyruvate kinase (PK) activator approved by the European Commission in 2022 for adults with Pyruvate Kinase (PK) Deficiency and in 2026 for anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia. Commercialized by Avanzanite under exclusive agreement with Agios Pharmaceuticals across the EEA, UK, and Switzerland for healthcare providers treating these rare hematological conditions.
  • Sibnayal A medicinal product approved by the European Commission in 2021 for the treatment of distal Renal Tubular Acidosis (dRTA), a rare kidney disease. Distributed by Avanzanite under an exclusive distribution agreement with Advicenne across Germany, Austria, Switzerland, Liechtenstein, Greece, Ireland, Cyprus, and Malta for patients with this rare renal condition.
  • AKANTIOR A medicinal product approved by the European Commission in 2024 for the treatment of Acanthamoeba Keratitis, a rare and severe ophthalmologic parasitic infection that accounts for 50% of blindness among contact lens users. Commercialized by Avanzanite under exclusive license and supply agreement with SIFI across 26 countries within the European Economic Area and Switzerland for affected patients and their treating ophthalmologists.
  • Pan-European Orphan Drug Commercialization Partnership End-to-end commercialization and distribution partnership service for emerging or early-stage biopharmaceutical originators with approved or late-stage orphan medicines. The service covers regulatory navigation, pricing and reimbursement negotiations, market access, medical affairs, and WDA-licensed physical distribution across 32 European countries (EEA, UK, Switzerland) under bespoke exclusive licensing or distribution agreements. Targeted at biotech originators that lack European infrastructure or face regulatory and market access complexity.

Quantifiable outcome

  • Revenue tripled year-over-year in Q3 2025 and climbed over 20% quarter-on-quarter
  • +2 more outcomes

Companies that use Avanzanite Bioscience

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Avanzanite Bioscience technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Avanzanite Bioscience partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, minor and core.

  • Agios PharmaceuticalsflagshipStrategic or Co-development Partner · 1 June 2025Avanzanite entered an exclusive agreement with Agios Pharmaceuticals in June 2025 to commercialize and distribute PYRUKYND (mitapivat) across the European Economic Area, UK, and Switzerland. PYRUKYND is a first-in-class oral pyruvate kinase activator approved for adults with PK deficiency and later for thalassemia. The partnership includes rights for potential future indications and represents Avanzanite's flagship rare disease launch.
  • NewBridge PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 1 January 2025Agios Pharmaceuticals established a revenue-sharing partnership with NewBridge Pharmaceuticals for the GCC region to commercialize PYRUKYND ex-U.S., pending regulatory approvals in those markets. Avanzanite is the equivalent partner for the European market.
  • AdvicennecoreChannel Partner/ Reseller/ Distributor · 1 February 2023Avanzanite signed an exclusive distribution agreement with Paris-based Advicenne for Sibnayal (ADV 7103), a medicinal product approved by the European Commission for the treatment of distal Renal Tubular Acidosis (dRTA). Avanzanite distributes Sibnayal in Germany, Austria, Switzerland, Greece, Ireland, Cyprus, and Malta, with first anticipated commercial launch in Germany in mid-2023.
  • SIFI S.p.A.coreStrategic or Co-development Partner · 1 January 2022Avanzanite holds exclusive license and supply agreement with SIFI for AKANTIOR (Acanthamoeba Keratitis treatment) across 26 countries within the EEA and Switzerland. SIFI partnered with Avanzanite to commercialize and distribute its investigational ultra-orphan medicine for the treatment of AK, a devastating eye infection that accounts for 50% of blindness among contact lens users.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Avanzanite Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Alexion / AstraZeneca Rare Disease: Alexion, operating as AstraZeneca's Rare Disease unit, is a global leader in commercializing rare disease therapeutics with established European infrastructure. Highly comparable therapeutic and commercial focus but at vastly larger scale and within a broader pharma portfolio.
  • BioMarin Pharmaceutical: BioMarin is a global biotechnology company focused exclusively on rare diseases with significant European commercial presence. Comparable orphan drug focus but with proprietary pipeline rather than in-licensed assets.
  • Chiesi Farmaceutici: Chiesi is a privately-held European-headquartered pharmaceutical company with a strong rare disease franchise (Chiesi Global Rare Diseases). Comparable focus on commercializing orphan drugs across European markets with established country-level infrastructure.

Emerging players

  • Ultragenyx Pharmaceutical: Ultragenyx is a mid-stage rare disease biotech commercializing multiple orphan therapies in Europe and globally. Comparable focus on ultra-rare diseases and European commercialization, though Ultragenyx owns its pipeline.
  • Orphalan: Orphalan is a European specialty pharmaceutical company focused exclusively on rare diseases, developing and commercializing orphan drugs across multiple European markets. Comparable focus on rare disease commercialization in Europe.
  • Theramex: Theramex is a global specialty pharmaceutical company focused on women's health and rare conditions across Europe with established country-level infrastructure. Comparable European rare disease commercialization focus within a narrower therapeutic scope.

Direct peers

  • Swedish Orphan Biovitrum (Sobi): Sobi is a Swedish-headquartered global biopharmaceutical company specializing in rare diseases across haematology, immunology and specialty care with deep pan-European commercialization infrastructure. Highly comparable to Avanzanite's orphan drug commercialization focus and European footprint.
  • Recordati Rare Diseases: Recordati Rare Diseases is a global pharmaceutical group with a dedicated rare disease business that acquires, licenses and distributes orphan drugs across Europe and the US. Comparable business model of in-licensing and commercializing rare disease products across multiple geographies.
  • Inceptua Group: Inceptua is a specialty pharmaceutical company providing commercialization, distribution and early access services for rare disease and specialty products across Europe. Comparable business model of helping biotech originators access European markets without building own infrastructure.
  • Tanner Pharma Group: Tanner Pharma provides specialty distribution, commercialization and managed access services for rare disease products globally. Comparable outsourced commercialization model targeting emerging biopharmaceutical companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Avanzanite Bioscience social profiles

Digital presence

Avanzanite Bioscience compliance and trust

Trust signal

Compliance2 records

Avanzanite Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avanzanite Bioscience leadership team

Management profile

Number of profiles

Profiles9 records

Avanzanite Bioscience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avanzanite Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avanzanite Bioscience

What does Avanzanite Bioscience do?

Avanzanite offers end-to-end commercialization and distribution partnerships to research-based biopharmaceutical originators, licensing their approved or late-stage orphan medicines and bringing them to patients across 32 European countries. The company handles regulatory navigation, pricing and reimbursement, market access, medical affairs, and physical distribution, enabling biotech innovators to unlock European value of their rare disease therapies without building local infrastructure. Three products are currently commercialized under this model: PYRUKYND, Sibnayal, and AKANTIOR.

Is Avanzanite Bioscience a public or private company?

Avanzanite Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Avanzanite Bioscience founded?

Avanzanite Bioscience was founded in 2022. It employs 51 to 100 people.

Where is Avanzanite Bioscience based?

Avanzanite Bioscience is headquartered in Amsterdam, Netherlands, in the Europe region.

How does Avanzanite Bioscience make money?

One revenue line is on record: licensing and Distribution Partnerships.

Who are Avanzanite Bioscience's main competitors?

Broad incumbents on record are Alexion / AstraZeneca Rare Disease, BioMarin Pharmaceutical and Chiesi Farmaceutici. Emerging players are Ultragenyx Pharmaceutical, Orphalan and Theramex. Direct peers are Swedish Orphan Biovitrum (Sobi), Recordati Rare Diseases, Inceptua Group and Tanner Pharma Group.

Does Avanzanite Bioscience have an API?

No public API is recorded for Avanzanite Bioscience.

What industry is Avanzanite Bioscience in?

Avanzanite Bioscience's product category is Specialty Pharmaceuticals / Orphan Drug Commercialization. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienLizenz- und Liefervereinbarungen für Zemcelpro (UM171-Zelltherapie) in Europa bekannt gegebenCordex Biologics announced exclusive licensing and supply agreements with Avanzanite Bioscience for Zemcelpro (UM171) in 32 countries, including the EU, UK, and Switzerland. The cell therapy is for hematologic malignancies, and the deal follows conditional EU approval. The partnership aims to expand patient access in Europe.LelezardAvanzanite Bioscience renforce sa présence au Royaume-Uni et nomme Sarah O'Connell au poste de directrice nationaleAvanzanite Bioscience announced the appointment of Sarah O'Connell as national director for the UK, reinforcing its long-term commitment to the market. The company, founded in 2022, has 13 UK-based collaborators and aims to help patients access rare-disease medicines through partnerships with the NHS and patient groups.Business Wire BlogAvanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country ManagerAvanzanite Bioscience expanded its UK presence and appointed Sarah O'Connell as UK Country Manager. The move strengthens its commitment to the UK and its ability to help patients access rare disease medicines. The UK expansion builds on an existing team of 13 employees, bringing the company's total to over 100 across 32 countries.FinancialContent Business PageMediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable CareThe Mediterranean Network for Haemoglobinopathies launched in Rome, bringing together clinicians and patient leaders from Cyprus, Greece, Italy, and TIF. Avanzanite Bioscience became founding sponsor to support an independent platform. The network will focus on blood supply, access, and evidence-based improvement.MorningstarMediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable CareThe Mediterranean Network for Haemoglobinopathies launched in Rome, bringing together clinicians and patient leaders from Cyprus, Greece, Italy, and TIF. Avanzanite Bioscience became founding sponsor, and members endorsed a Declaration of Intent to address blood supply, access, and innovation. The network will initially focus on four objectives, with experience shaping future expansion.AInvestAGIO Stock Surges 35% in Six Months: What's Driving It?Agios Pharmaceuticals shares have risen 35% over the past six months, driven by FDA approval of Aqvesme (mitapivat) in December 2025 as the first FDA-approved drug for alpha- or beta-thalassemia, with strong early prescription adoption and worldwide mitapivat revenues more than doubling year over year. The company has expanded globally through a partnership with Avanzanite Bioscience for European marketing and secured regulatory approvals across Gulf Council Countries, while also in-licensing cevidoplenib from South Korea's Oscotec for immune thrombocytopenia with up to $1 billion peak U.S. sales potential. Agios discontinued development of tebapivat for lower-risk myelodysplastic syndromes last month after a mid-stage study failed to meet efficacy targets, though the drug remains in a phase II study for sickle cell disease.AijournAvanzanite Expands into Spain and Appoints María Baquerizo as Country ManagerAvanzanite Bioscience B.V. announced its expansion into Spain, appointing María Baquerizio López-Quectuy as Spain Country Manager, marking the fifth country where the company has established a legal entity in the past 12 months. The expansion follows a €32 million Series A investment by MVM Partners announced in November 2025 and recent entry into France. María will oversee all local regulatory, commercial, medical, market access, patient advocacy and operational activities from Madrid, reporting to the General Manager of Southern Europe.BioSpaceAvanzanite Expands into Spain and Appoints María Baquerizo as Country ManagerAvanzanite Bioscience appointed María Baquerizo López-Quectuy as Spain Country Manager, expanding its presence in the country. The move follows a €32 million Series A investment by MVM Partners and entry into France. Spain is the fifth country to have an Avanzanite legal entity in 12 months.Business Wire BlogAvanzanite Expands into Spain and Appoints María Baquerizo as Country ManagerAvanzanite Bioscience expanded into Spain, appointing María Baquerizo López-Quectuy as Country Manager. The move follows a €32 million Series A investment and entry into France, with Spain as the fifth country to have an Avanzanite legal entity in 12 months. Her team will focus on regulatory, commercial, and market access activities.Investing.comEU approves mitapivat for thalassaemia treatment in adults By Investing.comThe European Commission granted marketing authorization for mitapivat (marketed as PYRUKYND), an oral pyruvate kinase activator, for treating anemia in adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, based on results from Phase 3 ENERGIZE and ENERGIZE-T trials. Avanzanite Bioscience B.V. will commercialize and distribute the treatment across 32 European countries under an exclusive agreement with Agios Pharmaceuticals (NASDAQ:AGIO), which reported 78% revenue growth over the last twelve months. This marks the second indication for PYRUKYND in the EU, following its 2022 approval for adults with pyruvate kinase deficiency.